Open date: November 13th, 2020
Next review date: Monday, Dec 14, 2020 at 11:59pm (Pacific Time)
Apply by this date to ensure full consideration by the committee.
Final date: Sunday, Jan 31, 2021 at 11:59pm (Pacific Time)
Applications will continue to be accepted until this date, but those received after the review date will only be considered if the position has not yet been filled.
The Liquid Biopsy Program associated with the Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, and California NanoSystems Institute at UCLA is actively hiring full-time postdoctoral researchers to work in the interdisciplinary research team to develop precision-medicine-based diagnostic strategies for cancer and prenatal diseases.
With stable funding support from National Cancer Institute, the Liquid Biopsy Program at UCLA has assembled a group of scientists, engineers, and physicians from UCLA and Cedars Sinai Medical Center to leverage advances in nanotechnology to create tools that enable physicians to diagnose multiple types of cancer and prenatal diseases with improved precision and minimum invasiveness.
The ideal candidate should have a Ph.D. degree in molecular biology, biochemistry, or a related field. Previous experience with digital PCR, next-generation sequencing, molecular assay development, and/or liquid biopsy biomarkers is highly desirable.
Interested candidates should submit a brief cover letter and curriculum vitae.